General condition at discharge | All patients (n = 960) | Q1 (n = 318) Osm < 293.2 | Q2 (n = 322) 293.2 ≤ Osm < 300.3 | Q3 (n = 320) 300.3 ≤ Osm | P-value |
---|---|---|---|---|---|
BMI, kg/m2 | 21.4 (18.9–24.2) | 21.1 (18.4–23.8)‡ | 21.2 (18.7–24.3) | 21.9 (19.4–24.6)* | 0.0150 |
SBP, mmHg | 118 (106–131) | 117 (106–128)‡ | 118 (106–130) | 122 (107–134)* | 0.0106 |
DBP, mmHg | 65 (58–73) | 65 (58–73) | 66 (58–74) | 65 (57–73) | 0.7041 |
Heart rate | 70 (61–80) | 70 (63–80) | 70 (61–80) | 70 (60–78) | 0.5914 |
AF | 365 (38) | 124 (39) | 131 (41) | 110 (34) | 0.2242 |
GNRI | 92 (85–99) | 91 (84–97) | 94 (85–101) | 92 (85–99) | 0.1277 |
6MWD, m | 260 (155–340) | 240 (150–333) | 270 (156–352) | 260 (160–338) | 0.5728 |
NYHA classification | Â | Â | Â | Â | 0.6460 |
NYHA I | 340 (36) | 111 (36) | 106 (33) | 123 (39) | Â |
NYHA II | 538 (57) | 173 (55) | 193 (60) | 172 (54) | Â |
NYHA III | 67 (7) | 26 (8) | 20 (6) | 21 (7) | Â |
NYHA IV | 4 (0.4) | 2 (0.6) | 1 (0.3) | 1 (0.3) | Â |
Laboratory examination at discharge | Â | Â | Â | Â | Â |
Hemoglobin, g/dL | 11.3 (10.1–12.7) | 11.5 (10.3–12.7)‡ | 11.6 (10.4–13.1)‡ | 10.8 (9.5–12.2)*,†|  < 0.0001 |
Hematocrit, % | 34 (31–39) | 35 (32–38)‡ | 35 (32–39)‡ | 33 (30–37)*,†|  < 0.0001 |
Serum total protein, g/dL | 6.6 (6.2–7.1) | 6.8 (6.3–7.2)‡ | 6.8 (6.3–7.2)‡ | 6.5 (6.1–7.0)*,†| 0.0009 |
Serum albumin, g/dL | 3.4 (3.1–3.7) | 3.4 (3.1–3.7) | 3.4 (3.2–3.8)‡ | 3.3 (3.1–3.6)†| 0.0104 |
BUN, mg/dL | 25 (18–34) | 22 (16–28)†,‡ | 25 (18–33)*,‡ | 29 (21–42)*,†|  < 0.0001 |
Creatinine, μmol/L | 1.1 (0.9–1.5) | 1.0 (0.8–1.2)†,‡ | 1.1 (0.9–1.5)*,‡ | 1.3 (1.0–2.1)*,†|  < 0.0001 |
eGFR, mL/min/1.73m2 | 42 (30–55) | 50 (37–60)†,‡ | 42 (32–54)*,‡ | 33 (21–49)*,†|  < 0.0001 |
Serum sodium, mEq/L | 139 (137–141) | 138 (135–140)†,‡ | 140 (138–141)*,‡ | 140 (138–142)* |  < 0.0001 |
Serum potassium, mEq/L | 4.3 (3.9–4.6) | 4.3 (3.9–4.6) | 4.3 (4.0–4.6) | 4.3 (3.9–4.6) | 0.8271 |
Serum chloride, mEq/L | 103 (100–106) | 102 (99–105†,‡ | 103 (100–105)*,‡ | 104 (101–107)*,†|  < 0.0001 |
NT–proBNP, ng/L | 1112 (478–2550) | 993 (497–2190)‡ | 952 (439–2025)‡ | 1437 (510–3770)*,†| 0.0010 |
CRP, mg/dL | 0.29 (0.11–0.90) | 0.34 (0.11–1.01) | 0.28 (0.11–0.77) | 0.26 (0.11–0.93) | 0.4804 |
Glucose, mg/dL | 98 (88–117) | 97 (87–114) | 98 (88–117) | 101 (89–120) | 0.3746 |
PVS, % | 11.5 (1.9–19.6) | 9.9 (1.9–20.0) | 9.6 (0.9–17.9)‡ | 13.4 (3.1–21.2)†| 0.0411 |
Plasma osmolality, mOsm/kg | 294 (289–299) | 290 (286–295)†,‡ | 294 (290–299)*,‡ | 297 (293–302)*,†|  < 0.0001 |
Prescription at discharge | Â | Â | Â | Â | Â |
Antiplatelet | 278 (29) | 82 (26) | 93 (29) | 103 (32) | 0.1946 |
ACE inhibitor or ARB | 510 (53) | 157 (49) | 168 (52) | 185 (58) | 0.0935 |
Calcium channel blocker | 458 (48) | 135 (42)‡ | 149 (46) | 174 (55)* | 0.0076 |
β-blocker | 526 (55) | 167 (53) | 181 (56) | 178 (56) | 0.5896 |
Loop diuretics | 754 (79) | 243 (76) | 254 (79) | 257 (80) | 0.4793 |
Thiazide | 62 (6) | 18 (6) | 16 (5) | 28 (9) | 0.1165 |
Tolvaptan | 156 (16) | 39 (12)‡ | 54 (17) | 63 (20)* | 0.0377 |
Aldosterone antagonist | 383 (40) | 125 (39) | 141 (44) | 117 (37) | 0.1683 |
SGLT2 inhibitor | 50 (5) | 13 (4) | 12 (4) | 25 (8) | 0.0356 |
Anticoagulant | 571 (59) | 206 (65)‡ | 198 (61) | 167 (52)* | 0.0035 |